- Home
- BABA vs AZN Comparison
BABA vs AZN Comparison
Compare BABA & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BABA | AZN |
|---|---|---|
| Founded | 1999 | 1992 |
| Country | Hong Kong | United Kingdom |
| Employees | 128197 | 96100 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.4B | 316.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BABA | AZN |
|---|---|---|
| Price | $129.60 | $187.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 1 |
| Target Price | ★ $185.15 | N/A |
| AVG Volume (30 Days) | ★ 9.3M | 1.8M |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | 0.81% | ★ 1.73% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.05 | $10.34 |
| Revenue Next Year | $10.83 | $6.43 |
| P/E Ratio | ★ $21.20 | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $107.19 | $68.62 |
| 52 Week High | $192.67 | $212.71 |
Technical Indicators
Market Signals| Indicator | BABA | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 43.74 | 49.79 |
| Support Level | $129.29 | $180.98 |
| Resistance Level | $140.72 | $208.61 |
| Average True Range (ATR) | 4.43 | 3.00 |
| MACD | -0.92 | 0.80 |
| Stochastic Oscillator | 14.24 | 66.00 |
Price Performance
Historical ComparisonAbout BABA Alibaba Group Holding Limited
Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China retail e-commerce platform is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China wholesale e-commerce, international retail and wholesale e-commerce, local consumer services, travel services, cloud computing, digital media and entertainment, Cainiao logistics services, and other businesses.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.